These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 20427701)

  • 1. Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia.
    Balakrishnan K; Verma D; O'Brien S; Kilpatrick JM; Chen Y; Tyler BF; Bickel S; Bantia S; Keating MJ; Kantarjian H; Gandhi V; Ravandi F
    Blood; 2010 Aug; 116(6):886-92. PubMed ID: 20427701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells.
    Balakrishnan K; Nimmanapalli R; Ravandi F; Keating MJ; Gandhi V
    Blood; 2006 Oct; 108(7):2392-8. PubMed ID: 16778146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).
    Gandhi V; Kilpatrick JM; Plunkett W; Ayres M; Harman L; Du M; Bantia S; Davisson J; Wierda WG; Faderl S; Kantarjian H; Thomas D
    Blood; 2005 Dec; 106(13):4253-60. PubMed ID: 16131572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Forodesine (BCX-1777, Immucillin H)--a new purine nucleoside analogue: mechanism of action and potential clinical application.
    Korycka A; Błoński JZ; Robak T
    Mini Rev Med Chem; 2007 Sep; 7(9):976-83. PubMed ID: 17897085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells.
    Balakrishnan K; Burger JA; Quiroga MP; Henneberg M; Ayres ML; Wierda WG; Gandhi V
    Blood; 2010 Aug; 116(7):1083-91. PubMed ID: 20442367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia.
    Balakrishnan K; Ravandi F; Bantia S; Franklin A; Gandhi V
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):458-66. PubMed ID: 23773454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM.
    Alonso R; López-Guerra M; Upshaw R; Bantia S; Smal C; Bontemps F; Manz C; Mehrling T; Villamor N; Campo E; Montserrat E; Colomer D
    Blood; 2009 Aug; 114(8):1563-75. PubMed ID: 19541822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome).
    Dummer R; Duvic M; Scarisbrick J; Olsen EA; Rozati S; Eggmann N; Goldinger SM; Hutchinson K; Geskin L; Illidge TM; Giuliano E; Elder J; Kim YH
    Ann Oncol; 2014 Sep; 25(9):1807-1812. PubMed ID: 24948692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology and mechanism of action of forodesine, a T-cell targeted agent.
    Gandhi V; Balakrishnan K
    Semin Oncol; 2007 Dec; 34(6 Suppl 5):S8-12. PubMed ID: 18086347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A nelarabine-resistant T-lymphoblastic leukemia CCRF-CEM variant cell line is cross-resistant to the purine nucleoside phosphorylase inhibitor forodesine.
    Yamauchi T; Uzui K; Nishi R; Tasaki T; Ueda T
    Anticancer Res; 2014 Sep; 34(9):4885-92. PubMed ID: 25202070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug evaluation: forodesine - PNP inhibitor for the treatment of leukemia, lymphoma and solid tumor.
    Galmarini CM
    IDrugs; 2006 Oct; 9(10):712-22. PubMed ID: 17016779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)--a novel potent and orally active immunosuppressive agent.
    Bantia S; Miller PJ; Parker CD; Ananth SL; Horn LL; Kilpatrick JM; Morris PE; Hutchison TL; Montgomery JA; Sandhu JS
    Int Immunopharmacol; 2001 Jun; 1(6):1199-210. PubMed ID: 11407314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma.
    Maruyama D; Tsukasaki K; Uchida T; Maeda Y; Shibayama H; Nagai H; Kurosawa M; Suehiro Y; Hatake K; Ando K; Yoshida I; Hidaka M; Murayama T; Okitsu Y; Tsukamoto N; Taniwaki M; Suzumiya J; Tamura K; Yamauchi T; Ueda R; Tobinai K
    Ann Hematol; 2019 Jan; 98(1):131-142. PubMed ID: 29974231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Purine nucleoside phosphorylase inhibition as a novel therapeutic approach for B-cell lymphoid malignancies.
    Furman RR; Hoelzer D
    Semin Oncol; 2007 Dec; 34(6 Suppl 5):S29-34. PubMed ID: 18086344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SAMHD1 Limits the Efficacy of Forodesine in Leukemia by Protecting Cells against the Cytotoxicity of dGTP.
    Davenne T; Klintman J; Sharma S; Rigby RE; Blest HTW; Cursi C; Bridgeman A; Dadonaite B; De Keersmaecker K; Hillmen P; Chabes A; Schuh A; Rehwinkel J
    Cell Rep; 2020 May; 31(6):107640. PubMed ID: 32402273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Forodesine in the treatment of cutaneous T-cell lymphoma.
    Lewis DJ; Duvic M
    Expert Opin Investig Drugs; 2017 Jun; 26(6):771-775. PubMed ID: 28447489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor--BCX-1777.
    Bantia S; Ananth SL; Parker CD; Horn LL; Upshaw R
    Int Immunopharmacol; 2003 Jun; 3(6):879-87. PubMed ID: 12781704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent orally bioavailable purine nucleoside phosphorylase inhibitor BCX-4208 induces apoptosis in B- and T-lymphocytes--a novel treatment approach for autoimmune diseases, organ transplantation and hematologic malignancies.
    Bantia S; Parker C; Upshaw R; Cunningham A; Kotian P; Kilpatrick JM; Morris P; Chand P; Babu YS
    Int Immunopharmacol; 2010 Jul; 10(7):784-90. PubMed ID: 20399911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and pharmacokinetic and pharmacodynamic evaluation of the forodesine HCl analog BCX-3040.
    Kezar HS; Kilpatrick JM; Phillips D; Kellogg D; Zhang J; Morris PE
    Nucleosides Nucleotides Nucleic Acids; 2005; 24(10-12):1817-30. PubMed ID: 16438050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.
    Gandhi V; Kemena A; Keating MJ; Plunkett W
    Cancer Res; 1992 Feb; 52(4):897-903. PubMed ID: 1737352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.